Abby's valuation already reflects the coming sales decline for himeran and sas formere will decline, for sure. Adve's successors to humera are expected to together make 15 billion dollars in sales in 20 25. That will go a long way toward offsetting the declining sales for humera. The bottom line is that b will definitely feel some pain from biosimilar competition in the us. Market for humera, but the company should be in good shape to weather this storm.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode